Drug Trial Radar · NCT07750665
FXS6837 for the Treatment for IgAN Patients(Longterm Study)
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Nov 13, 2029
Study completion Jan 4, 2030
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.
Conditions
- Primary IgAN
Interventions
FXS6837 CapsuleDrug
FXS6837 capsule orally taken according to protocol for 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: through study completion, an average of 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.